These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

715 related articles for article (PubMed ID: 35944490)

  • 1. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
    Dariane C; Timsit MO
    Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States.
    McKay RR; Morgans AK; Shore ND; Dunshee C; Devgan G; Agarwal N
    Cancer Treat Rev; 2024 May; 126():102726. PubMed ID: 38613872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis.
    Messina C; Giunta EF; Signori A; Rebuzzi SE; Banna GL; Maniam A; Buti S; Cattrini C; Fornarini G; Bauckneht M; Greystoke A; Plummer R; Oing C; Rescigno P
    Eur Urol Oncol; 2024 Apr; 7(2):179-188. PubMed ID: 37574390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
    de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K
    Lancet Oncol; 2021 Sep; 22(9):1250-1264. PubMed ID: 34388386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis.
    Zhu Q; Chen J; Liu H; Zhao J; Xu C; Sun G; Zeng H
    BMC Cancer; 2024 Jun; 24(1):706. PubMed ID: 38851712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer.
    Su CT; Nizialek E; Berchuck JE; Vlachostergios PJ; Ashkar R; Sokolova A; Barata PC; Aggarwal RR; McKay RR; Agarwal N; McClure HM; Nafissi N; Bryce AH; Sartor O; Sayegh N; Cheng HH; Adra N; Sternberg CN; Taplin ME; Cieslik M; Alva AS; Antonarakis ES
    Prostate; 2023 Feb; 83(3):227-236. PubMed ID: 36382533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.
    Olmos D; Lorente D; Alameda D; Cattrini C; Romero-Laorden N; Lozano R; Lopez-Casas PP; Jambrina A; Capone C; Vanden Broecke AM; Trevisan M; Van Sanden S; Jürgens A; Herrera-Imbroda B; Castro E
    Ann Oncol; 2024 May; 35(5):458-472. PubMed ID: 38417742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides
    Voutsadakis IA; Stravodimou A
    Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
    Antonarakis ES; Gomella LG; Petrylak DP
    Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emerging role of PARP inhibitors in prostate cancer.
    Stellato M; Guadalupi V; Sepe P; Mennitto A; Claps M; Zattarin E; Verzoni E; Valdagni R; De Braud FG; Santini D; Tonini G; Procopio G
    Expert Rev Anticancer Ther; 2020 Aug; 20(8):715-726. PubMed ID: 32758032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer.
    Unlu S; Kim JW
    Curr Oncol Rep; 2022 Nov; 24(11):1619-1631. PubMed ID: 35931885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How the Analysis of the Pathogenetic Variants of DDR Genes Will Change the Management of Prostate Cancer Patients.
    Sciarra A; Frisenda M; Bevilacqua G; Gentilucci A; Cattarino S; Mariotti G; Del Giudice F; Di Pierro GB; Viscuso P; Casale P; Chung BI; Autorino R; Crivellaro S; Salciccia S
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
    Cerrato A; Morra F; Celetti A
    J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.
    Fallah J; Xu J; Weinstock C; Gao X; Heiss BL; Maguire WF; Chang E; Agrawal S; Tang S; Amiri-Kordestani L; Pazdur R; Kluetz PG; Suzman DL
    J Clin Oncol; 2024 May; 42(14):1687-1698. PubMed ID: 38484203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
    Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prognostic Significance of Homologous Recombination Repair Pathway Alterations in Metastatic Hormone Sensitive Prostate Cancer.
    Lee AM; Saidian A; Shaya J; Nonato T; Cabal A; Randall JM; Millard F; Stewart T; Rose B; Tamayo P; McKay RR
    Clin Genitourin Cancer; 2022 Dec; 20(6):515-523. PubMed ID: 35871039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining Novel Hormonal Therapies with a Poly (ADP-Ribose) Polymerase Inhibitor for Metastatic Castration-Resistant Prostate Cancer: Emerging Evidence.
    Yang J; Xiong X; Zheng W; Liao X; Xu H; Yang L; Wei Q
    Curr Oncol; 2023 Dec; 30(12):10311-10324. PubMed ID: 38132385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data.
    Sigorski D; Iżycka-Świeszewska E; Bodnar L
    Target Oncol; 2020 Dec; 15(6):709-722. PubMed ID: 33044685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
    Rimar KJ; Tran PT; Matulewicz RS; Hussain M; Meeks JJ
    Cancer; 2017 Jun; 123(11):1912-1924. PubMed ID: 28323334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Research progress on the treatment of advanced prostate cancer with Olaparib.
    Su YX; Yu CF; Xue P; Li LL; Xiao KM; Chu XL; Zhu SJ
    Neoplasma; 2021 Nov; 68(6):1132-1138. PubMed ID: 34779643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.